| Ticker: NPRM | 225 East Deerpath, Suite 250 | |
| Exchange: NASDAQ-Small Cap Market | Lake Forest, Illinois 60045 | |
| Industry: Manufacturing | (708) 295-8678 |
| Type of Shares: | Common Shares | Filing Date: | 3/22/95 | |
| U.S. Shares: | 1,350,000 | Offer Date: | 1/25/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $7.00 - $9.00 | |
| Primary Shares: | 1,350,000 | Offer Price: | $7.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.59 | |
| Offering Amount: | $10,800,000 | Selling: | $0.35 | |
| Expenses: | $500,000 | Reallowance: | $0.10 | |
| Shares Out After: | 3,700,000 |
| Manager | Tier | Phone |
| National Securities Corp. | Lead Manager | (206) 622-7200 |
| Auditor: Arthur Andersen | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/94 | 9/30/95 | 9/30/94 | 9/30/95 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $6.34 |
| Net Income: | -$1.08 | -$1.30 | -$0.75 | Liabilities: | $10.33 |
| EPS: | -$0.49 | -$0.44 | -$0.35 | Equity: | -$3.99 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a pharmaceutical company engaged in the research and development of drugs for the diagnosis and treatment of various forms of cancer. Phase II clinical trials have been completed by various parties under the sponsorship of the National Cancer Institute, and unit of the National Institutes of Health, with respect to the company's two primary drugs, BUdR (Broxuridine) and IUdR (Idoxurine). In clinical trials involving brain cancer patients, patients receiving BUdR together with radiation therapy exhibited increased survival times as compared to patients receiving radiation therapy alone. Preliminary results of additional studies indicate that BUdR and IUdR may enhance the effectiveness of radiation therapy for other cancers, including cervical and gynecological cancers, soft tissue sarcomas, and head and neck cancers. The company also has developed proprietary liposome products. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research and development, clinical trials, repayment of bank debt, sales and marketing efforts, working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.